Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Donald Denkhaus Insider Profile
4 Followers
Donald Denkhaus, Director at Catalyst Pharma, holds 438.33K shares in Catalyst Pharma (Ticker: CPRX). Most recently, Donald Denkhaus Bought $40,000 shares of Catalyst Pharma on Feb 06, 2024 for an estimated value of 160.40K.
Profitable Transactions
7 out of 14 Profitable Transactions
Average Return
+12.00%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Donald Denkhaus's holdings
Insider Roles
Director
Roles that Donald Denkhaus holds in companies
Most Profitable Insider Trade
The most profitable trade made by Donald Denkhaus
Donald Denkhaus's Trading History
List of latest transactions for each holding click on a transaction to see Donald Denkhaus's performance on stock
You May Also Like
Donald Denkhaus insider profile FAQ
What is the percentage of profitable transactions made by Donald Denkhaus?
The percentage of profitable transactions made by Donald Denkhaus is 50%.
What is the average return per transaction made by Donald Denkhaus?
The average return per transaction made by Donald Denkhaus is 12.00%.
What stocks does Donald Denkhaus hold?
Donald Denkhaus holds: CPRX stocks.
What was Donald Denkhaus’s latest transaction?
Donald Denkhaus latest transaction was an Informative Buy of $160.40K.
What was Donald Denkhaus's most profitable transaction?
Donald Denkhaus’s most profitable transaction was an Informative Buy of CPRX stock on June 14, 2016. The return on the trade was 234.20%.
What is Donald Denkhaus's role in Catalyst Pharma?
Donald Denkhaus's role in Catalyst Pharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.